Menu
Home Explore People Places Arts History Plants & Animals Science Life & Culture Technology
On this page
Peginterferon beta-1a
Pharmaceutical drug

Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.

The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.

Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.

We don't have any images related to Peginterferon beta-1a yet.
We don't have any YouTube videos related to Peginterferon beta-1a yet.
We don't have any PDF documents related to Peginterferon beta-1a yet.
We don't have any Books related to Peginterferon beta-1a yet.
We don't have any archived web articles related to Peginterferon beta-1a yet.

Medical uses

In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.7

In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.8

References

  1. "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Retrieved 25 June 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08f0ea03-4e6d-195d-aef4-886e32befa95 ↩

  2. "Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy ↩

  3. "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Retrieved 25 June 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08f0ea03-4e6d-195d-aef4-886e32befa95 ↩

  4. "Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy ↩

  5. "Drug Approval Package: Plegridy (peginterferon beta-1a) prefilled syringe and Plegridy Pen (peginterferon beta-1a) prefilled pen NDA #125499". U.S. Food and Drug Administration (FDA). 17 September 2014. Retrieved 25 June 2020. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125499Orig1s000TOC.cfm ↩

  6. "Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy ↩

  7. "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Retrieved 25 June 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08f0ea03-4e6d-195d-aef4-886e32befa95 ↩

  8. "Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy ↩